About
Technology
Issues
FAQ
Links
Official Page
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.